On the public citation graph
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
0 signed · 67 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0openalex-snapshot
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
inferredcites →https://doi.org/10.1002/hep.22106openalex-snapshot
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
inferredcites →https://doi.org/10.1002/hep.26718openalex-snapshot
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
inferredcites →https://doi.org/10.1002/jmv.10430openalex-snapshot
Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study
inferredcites →https://doi.org/10.1007/s12072-015-9675-4openalex-snapshot
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
inferredcites →https://doi.org/10.1016/j.jcv.2013.08.012openalex-snapshot
Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010
inferredcites →https://doi.org/10.1016/j.jfma.2015.06.003openalex-snapshot
Perspectives and control of hepatitis B virus infection in Taiwan
inferredcites →https://doi.org/10.1016/j.jhep.2018.02.033openalex-snapshot
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
inferredcites →https://doi.org/10.1016/s0140-6736(15)61412-xopenalex-snapshot
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
inferredcites →https://doi.org/10.1016/s1470-2045(11)70393-xopenalex-snapshot
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
inferredcites →https://doi.org/10.1038/sj.bjc.6601699openalex-snapshot
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
inferredcites →https://doi.org/10.1053/j.gastro.2014.10.039openalex-snapshot
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
inferredcites →https://doi.org/10.1053/j.gastro.2017.02.009openalex-snapshot
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
inferredcites →https://doi.org/10.1080/10245332.2017.1321882openalex-snapshot
Hepatitis B reactivation in patients receiving targeted therapies
inferredcites →https://doi.org/10.1111/j.1440-1746.2010.06243.xopenalex-snapshot
Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management
inferredcites →https://doi.org/10.1111/jvh.12402openalex-snapshot
Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis
inferredcites →https://doi.org/10.1146/annurev.med.55.091902.104433openalex-snapshot
The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1182/blood.v128.22.5429.5429openalex-snapshot
Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1200/jco.2010.33.4235openalex-snapshot
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
inferredcites →https://doi.org/10.1200/jco.2011.35.1635openalex-snapshot
Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors
inferredcites →https://doi.org/10.1200/jco.2012.44.2806openalex-snapshot
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
inferredcites →https://doi.org/10.1200/jco.2014.56.7081openalex-snapshot
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
inferredcites →https://doi.org/10.1371/journal.pone.0179680openalex-snapshot
Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1634/theoncologist.2016-0331openalex-snapshot
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
inferredcites →https://doi.org/10.3747/co.22.2665openalex-snapshot
Reactivation of Hepatitis B Virus after Withdrawal of Erlotinib
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4856228openalex-extracted
Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers)
inferred← citeshttps://doi.org/10.1007/s11901-024-00662-7openalex-snapshot
A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators
inferred← citeshttps://doi.org/10.1007/s12072-021-10239-xopenalex-snapshot
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
inferred← citeshttps://doi.org/10.1007/s40278-019-65238-7openalex-snapshot
Epidermal growth factor receptor antagonists
inferred← citeshttps://doi.org/10.1016/j.bbrep.2020.100763openalex-snapshot
EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103127openalex-snapshot
Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103954openalex-snapshot
Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario
inferred← citeshttps://doi.org/10.1016/j.dld.2025.10.025openalex-snapshot
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società…
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.02.026openalex-snapshot
Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection
inferred← citeshttps://doi.org/10.1016/j.esmoop.2023.101560openalex-snapshot
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1016/j.idc.2020.02.009openalex-snapshot
Hepatitis B Virus Reactivation Potentiated by Biologics
inferred← citeshttps://doi.org/10.1016/j.isci.2025.112689openalex-snapshot
HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study
inferred← citeshttps://doi.org/10.1016/j.jfma.2021.03.023openalex-snapshot
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.07.003openalex-snapshot
Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion
inferred← citeshttps://doi.org/10.1016/s1877-1203(23)00161-1openalex-snapshot
Insuffisance d’organe (cœur, rein, foie) et traitements du cancer pulmonaire
inferred← citeshttps://doi.org/10.1038/s41598-025-13406-4openalex-snapshot
HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2024.08.001openalex-snapshot
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1080/17474124.2020.1774364openalex-snapshot
Hepatitis B reactivation: diagnosis and management
inferred← citeshttps://doi.org/10.1093/neuonc/noag036openalex-snapshot
Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR -mutant non–small-cell lung cancer patients with brain metastases: A phase I/II study
inferred← citeshttps://doi.org/10.1097/js9.0000000000001141openalex-snapshot
Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China
inferred← citeshttps://doi.org/10.1097/mjt.0000000000001695openalex-snapshot
Hepatitis B Virus Reactivation After Pralsetinib-Targeted Therapy in a Patient With Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.14346openalex-snapshot
Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
inferred← citeshttps://doi.org/10.1136/bmj-2024-079579openalex-snapshot
Advances in the management of hepatitis B
inferred← citeshttps://doi.org/10.1136/bmj.m2200openalex-snapshot
Hepatitis B virus persistence and reactivation
inferred← citeshttps://doi.org/10.1155/2021/6225403openalex-snapshot
Big Data Information under Proportional Hazard Mathematical Model in Analysis of Hepatitis B Virus Infection Data of Patients with Interventional Liver Cancer through Antiviral Therapy of Entecavir
inferred← citeshttps://doi.org/10.1177/1073274820976594openalex-snapshot
Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.21037/atm.2020.01.97openalex-snapshot
Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area
inferred← citeshttps://doi.org/10.21037/tlcr-21-79openalex-snapshot
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-9398320/v1openalex-snapshot
HBV reactivation and its management in patients with large HCC receiving TACE-TKI-ICI therapy: A retrospective study
inferred← citeshttps://doi.org/10.2147/jhc.s392347openalex-snapshot
Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2169/internalmedicine.2731-23openalex-snapshot
De novo Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer
inferred← citeshttps://doi.org/10.22551/2023.41.1004.10266openalex-snapshot
From spotlight to shadow: ALK inhibitor-induced acute liver failure in a patient with non-small cell lung cancer
inferred← citeshttps://doi.org/10.3389/fphar.2021.660710openalex-snapshot
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
inferred← citeshttps://doi.org/10.3390/biom13101438openalex-snapshot
cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels
inferred← citeshttps://doi.org/10.3390/cancers15061766openalex-snapshot
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
inferred← citeshttps://doi.org/10.3390/ijms21082774openalex-snapshot
Non-Coding RNAs in Lung Tumor Initiation and Progression
inferred← citeshttps://doi.org/10.3390/jcm12010231openalex-snapshot
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
inferred← citeshttps://doi.org/10.3390/v15112254openalex-snapshot
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19
inferred← citeshttps://doi.org/10.3748/wjg.v30.i24.3052openalex-snapshot
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2021.102.32openalex-snapshot
[Recommendations from Experts in the Management of Adverse Reactions to ALK Inhibitors (2021 Version)].
inferred← citeshttps://doi.org/10.37796/2211-8039.1186openalex-snapshot
Study of the D-dimer, C-reactive protein, and autoantibodies markers among HBV infected patients in Babylon province, Iraq
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.